PROTAC Market Forecast Signals Robust Growth Through 2034 Driven by Advancements in Targeted Protein Degradation Therapies

The PROTAC market is witnessing substantial momentum owing to the growing demand for next-generation targeted therapeutics capable of degrading disease-causing proteins previously considered “undruggable.” Rising investments in oncology research, rapid advances in targeted protein degradation (TPD) technologies, and increasing clinical success of investigational therapies such as vepdegestrant (ARV-471), ARV-110, HP518, and others are expected to significantly accelerate market expansion during the forecast period from 2024 to 2034.

The PROTAC market is rapidly evolving into one of the most promising therapeutic technology platforms in modern drug development. Unlike conventional small-molecule inhibitors that merely suppress protein activity, PROTACs (PROteolysis TArgeting Chimeras) selectively degrade harmful proteins through the ubiquitin-proteasome system, offering durable and catalytic therapeutic effects.

The increasing burden of cancers, autoimmune disorders, and neurodegenerative diseases has intensified the demand for innovative therapies capable of overcoming drug resistance and targeting previously inaccessible proteins such as KRAS, STAT3, androgen receptors, and estrogen receptors. The growing pipeline of clinical-stage PROTAC therapies, strategic collaborations among pharmaceutical companies, and favorable regulatory support are expected to propel the PROTAC market over the coming decade.

Recently published “PROTAC Market Forecast, Target Population, Competitive Landscape, and Market Forecast – 2034” report by DelveInsight provides a comprehensive assessment of the evolving PROTAC treatment landscape, including epidemiology trends, emerging therapeutics, market dynamics, pipeline analysis, competitive benchmarking, and forecasted market size across the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways from the PROTAC Market Report

• The PROTAC market is projected to witness substantial growth through 2034 owing to increasing clinical advancement of targeted protein degradation therapies.
• The United States is expected to dominate the PROTAC market among the 7MM due to strong R&D investment, higher adoption of precision medicine, and robust oncology clinical trial activity.
• Several leading PROTAC companies, including Pfizer/Arvinas, Celgene/Bristol Myers Squibb, Hinova Pharmaceuticals, Kymera Therapeutics, Nurix Therapeutics, Dialectic Therapeutics, and others, are actively developing innovative PROTAC candidates across oncology and autoimmune indications.
• Vepdegestrant (ARV-471), jointly developed by Pfizer and Arvinas, remains one of the most advanced investigational PROTAC therapies and is currently under evaluation in Phase III VERITAC-2 and VERITAC-3 clinical studies.
• In February 2024, vepdegestrant received FDA Fast Track Designation for adult patients with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy.
• Emerging PROTAC therapies such as ARV-110, CC-94676, HP518, KT-474, NX-2127, NX-5948, DT2216, and others are expected to reshape the future treatment landscape.
• Increasing investments in AI-enabled drug discovery, structural biology, and proteomics are accelerating the design and optimization of novel PROTAC molecules.

Discover how targeted protein degradation is transforming oncology therapeutics @ PROTAC Market Forecast Report

Key Factors Driving the PROTAC Market Growth

Novel Mechanism of Action with Therapeutic Advantage

PROTACs represent a revolutionary therapeutic strategy because they induce selective degradation of disease-causing proteins rather than merely inhibiting their activity. By leveraging the body’s natural ubiquitin-proteasome system, PROTAC molecules can repeatedly eliminate pathogenic proteins with catalytic efficiency. This approach enables the targeting of proteins previously considered inaccessible through conventional therapeutic approaches.

Rising Prevalence of Target Diseases

The increasing prevalence of hormone receptor-positive breast cancer, metastatic prostate cancer, autoimmune diseases, and neurodegenerative disorders is fueling demand for advanced targeted therapies. Since PROTACs can selectively degrade proteins central to disease progression, they are emerging as promising therapeutic candidates across multiple disease categories.

Advancements in Drug Discovery Technologies

Rapid developments in computational biology, artificial intelligence, structural proteomics, and high-throughput screening technologies are streamlining the discovery and optimization of PROTAC molecules. These innovations are reducing development timelines and enabling the creation of highly selective protein degraders with improved pharmacological profiles.

Collaborative Research and Strategic Partnerships

Strategic alliances between biotechnology firms, pharmaceutical companies, and academic institutions continue to strengthen the PROTAC ecosystem. Partnerships such as Pfizer and Arvinas have accelerated the clinical development and commercialization potential of next-generation protein degraders.

Favorable Regulatory Environment

Regulatory agencies are increasingly recognizing the therapeutic potential of targeted protein degradation technologies. Expedited designations such as FDA Fast Track status for vepdegestrant highlight growing regulatory confidence in PROTAC therapies for serious and unmet medical conditions.

Explore the latest clinical and commercial developments in targeted protein degradation @ PROTAC Therapeutics Market Insights

Ramandeep Singh, Senior Consultant at DelveInsight, commented that “PROTAC technology is transforming the future of precision medicine by enabling selective degradation of disease-causing proteins that were previously difficult to target using traditional small molecules. As clinical evidence continues to mature, PROTAC therapies are expected to unlock significant therapeutic opportunities across oncology, immunology, and neurodegenerative diseases.”

PROTAC Market Analysis

Targeted Protein Degradation (TPD) has emerged as a transformative therapeutic modality capable of addressing disease-causing proteins that have historically remained beyond the reach of conventional therapeutic strategies. Among TPD technologies, PROTACs have gained exceptional attention due to their ability to recruit E3 ubiquitin ligases and direct pathogenic proteins toward degradation through the ubiquitin-proteasome system.

Unlike traditional inhibitors, PROTACs function catalytically and can repeatedly eliminate target proteins without requiring sustained occupancy. This unique mechanism may enable lower dosing requirements, improved efficacy, and reduced resistance development.

Currently, nearly 90 protein degradation-based candidates are under evaluation globally, with approximately 20% of therapies in clinical development stages and the remaining candidates in preclinical or discovery phases. PROTACs account for a significant proportion of the targeted protein degradation pipeline.

The oncology segment remains the primary focus area for PROTAC development, particularly in breast cancer and prostate cancer. However, emerging research is increasingly expanding into autoimmune diseases, inflammatory disorders, and neurodegenerative conditions.

Among the most advanced clinical candidates, vepdegestrant (ARV-471) has demonstrated strong potential as an estrogen receptor degrader for ER+/HER2- breast cancer. The therapy is currently being evaluated in multiple Phase III studies both as monotherapy and in combination regimens.

Meanwhile, ARV-110 (bavdegalutamide), another investigational PROTAC developed by Arvinas, targets androgen receptors in metastatic castration-resistant prostate cancer and has shown encouraging clinical activity.

Gain deeper insights into emerging PROTAC clinical programs and commercialization opportunities @ PROTAC Pipeline Analysis

PROTAC Competitive Landscape

Several biotechnology and pharmaceutical companies are actively competing in the rapidly evolving PROTAC market. Key companies include Pfizer/Arvinas, Celgene/Bristol Myers Squibb, Hinova Pharmaceuticals, Kymera Therapeutics, Nurix Therapeutics, Dialectic Therapeutics, Accutar Biotech, and others.

Vepdegestrant (ARV-471): Pfizer/Arvinas

Vepdegestrant is an investigational orally bioavailable PROTAC estrogen receptor degrader jointly developed by Pfizer and Arvinas. The therapy is designed using Arvinas’ proprietary PROTAC Discovery Engine platform and aims to selectively degrade estrogen receptor proteins implicated in breast cancer progression.

The therapy is currently under evaluation in the Phase III VERITAC-2 clinical trial as monotherapy and in the Phase III VERITAC-3 study in combination with palbociclib. Additional studies are exploring combination approaches involving abemaciclib, ribociclib, everolimus, samuraciclib, and Pfizer’s investigational CDK4 inhibitor PF-07220060.

ARV-110 (Bavdegalutamide): Arvinas

ARV-110 is an oral PROTAC degrader targeting androgen receptors in metastatic castration-resistant prostate cancer. The therapy promotes ubiquitination and degradation of androgen receptor proteins and has demonstrated encouraging antitumor activity in early clinical studies.

In March 2024, Arvinas announced plans to discuss alignment of the Phase III prostate cancer program with regulatory authorities.

HP518: Hinova Pharmaceuticals

HP518 is an investigational androgen receptor PROTAC degrader under evaluation for metastatic castration-resistant prostate cancer. Preliminary findings presented at ASCO GU 2024 demonstrated promising efficacy signals and favorable tolerability profiles in patients with androgen receptor ligand-binding domain mutations.

KT-474: Kymera Therapeutics/Sanofi

KT-474 is an IRAK4-targeted degrader being investigated for inflammatory and autoimmune disorders such as hidradenitis suppurativa, rheumatoid arthritis, and atopic dermatitis.

Learn which emerging companies are shaping the future of the PROTAC industry @ PROTAC Competitive Landscape Analysis

Recent Developments in the PROTAC Market

• In May 2026, Genexine, Inc. (KOSDAQ: 095700), a clinical-stage biotechnology company,  announced new preclinical data for its SOX2-targeting bioPROTAC candidate, GX-BP1, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego.
• In April 2026, Arvinas announced, Abstract CT268, a Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL)
• In March 2026, Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease (PD) will be presented at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026), March 17-21, 2026, in Copenhagen, Denmark. ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in PD and progressive supranuclear palsy (PSP).
• In October 2025, Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTAC KRAS G12D degrader, will be presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.
• In February 2024, vepdegestrant received FDA Fast Track Designation for ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy.
• In February 2024, Arvinas announced first-in-human dosing of ARV-102, an investigational PROTAC degrader targeting LRRK2 for neurodegenerative diseases.
• In March 2024, Arvinas announced discussions with regulatory authorities regarding advancement of ARV-110 into Phase III development for metastatic prostate cancer.
• At ASCO GU 2024, Hinova Pharmaceuticals presented encouraging clinical findings for HP518 in metastatic castration-resistant prostate cancer patients.
• Strategic collaborations and licensing agreements across the protein degradation sector continue to accelerate commercialization opportunities and expand global PROTAC pipelines.

What are PROTACs?

PROTACs, or PROteolysis TArgeting Chimeras, are bifunctional molecules engineered to selectively degrade disease-causing proteins using the cell’s ubiquitin-proteasome degradation machinery. A PROTAC molecule contains two binding domains connected through a linker: one domain binds the target protein, while the other recruits an E3 ubiquitin ligase.

Once both proteins are brought into proximity, the E3 ligase tags the target protein with ubiquitin molecules, signaling the proteasome to degrade it. This mechanism enables complete elimination of pathogenic proteins rather than temporary inhibition.

PROTACs can be broadly classified into three categories:

• Traditional Small-Molecule PROTACs
• BioPROTACs
• Hybrid PROTACs

These technologies are increasingly recognized as paradigm-shifting innovations capable of transforming the future of targeted therapeutics.

Stay ahead with emerging protein degradation technologies and market intelligence @ PROTAC Oncology Market Analysis

PROTAC Market Outlook

The PROTAC market is expected to witness robust growth during the forecast period due to increasing clinical validation of targeted protein degradation therapies. Although no PROTAC-based therapy has yet received commercial approval, the rapid progression of multiple late-stage candidates is generating strong industry optimism.

The successful transition of therapies such as ARV-110 and vepdegestrant into advanced clinical development has provided important proof-of-concept validation for the PROTAC modality. As clinical data matures, the market is expected to experience broader investment activity, partnership formation, and commercialization momentum.

The increasing ability of PROTACs to overcome resistance mechanisms, degrade undruggable targets, and achieve selective therapeutic activity positions them as one of the most promising next-generation drug discovery platforms.

Future opportunities are expected to expand beyond oncology into immunology, neuroscience, and rare diseases, creating substantial commercial potential for biotechnology and pharmaceutical stakeholders.

Scope of the PROTAC Market Report

• Study Period: 2020–2034
• Forecast Period: 2024–2034
• Geographies Covered: US, EU4 (Germany, France, Italy, Spain), UK, Japan
• Market Coverage: Total Market Size, Therapy-wise Market Size, Drug Class Analysis
• Key Companies: Pfizer/Arvinas, Celgene/BMS, Hinova Pharmaceuticals, Nurix Therapeutics, Kymera Therapeutics, and others
• Emerging Therapies: Vepdegestrant, ARV-110, HP518, KT-474, NX-2127, NX-5948, DT2216, and others
• Comprehensive assessment of current and emerging PROTAC therapies
• Detailed pipeline analysis and competitive benchmarking
• Market size estimates and forecasts across the 7MM
• SWOT analysis and strategic market intelligence
• KOL insights and treatment pattern evaluation
• Drug uptake projections and commercialization analysis
• Regulatory, licensing, and collaboration assessment
• Unmet needs and future market opportunities

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on life sciences and healthcare industries. The company supports pharmaceutical, biotechnology, and medical device organizations with comprehensive end-to-end market intelligence solutions designed to improve strategic decision-making and accelerate business growth.

DelveInsight’s industry-leading reports provide actionable insights into epidemiology, market forecasts, competitive intelligence, pipeline analysis, and emerging therapeutic opportunities across multiple disease domains.